Abstract
Incidental pathogenic germline variants (iPGV) in BRCA1/2 may be identified in patients with advanced non-small cell lung cancer (aNSCLC) by somatic genotyping via tissue or plasma-based assays. However, impact of iPGVs on patient outcomes is not well understood. Because of the sensitivity of BRCA-deficient cancers to various therapies, it is of interest to understand the impact of these iPGVs on molecularly homogenous lung cancer population. Using real-world evidence (RWE), we aimed to explore the impact of iPGV findings in BRCA1/2 (gBRCA), identified by a well-validated liquid biopsy assay, on outcomes in patients with aNSCLC who received EGFR targeted therapy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
